Research on type 1 diabetes advances: Florence’s Meyer is one of the protagonists
New monoclonal antibody designed to protect insulin-producing cells
The international study Fabulinus, of which the Diabetology of AOU Meyer Irccs in Florence is the only active Italian center, is opening new perspectives in the treatment of type 1 diabetes. At the center of research there is a new monoclonal antibody, a molecule designed to protect the beta cells of the pancreas, responsible for insulin production.
How does it work?
In type 1 diabetes, the immune system mistakenly attacks beta cells, preventing them from producing insulin needed to regulate blood glucose levels. The monoclonal antibody used in the Fabulinus study acts as a shield, protecting beta cells from this attack and allowing them to continue functioning. This could slow the progression of the disease and reduce dependence on exogenous insulin.
Impact on everyday life
Beta cell storage has a significant impact on the lives of patients with type 1 diabetes. Better metabolic control results in a reduced risk of developing long-term complications, such as cardiovascular disease, retinopathy and neuropathy. In addition, less dependence on insulin means more freedom and flexibility in managing the disease, with a positive impact on quality of life.
Challenges and future prospects
Despite promising results, research on type 1 diabetes is still ongoing. Further studies are needed to assess the long-term efficacy and safety of this new treatment. Scientists are also working to develop increasingly personalised therapeutic combinations, taking into account the individual characteristics of each patient.
The role of diet and lifestyle
It is important to note that the new therapies do not replace standard treatments, such as insulin therapy and glycemic monitoring. Proper nutrition, high in fiber and low in glycemic index, and regular physical activity remain essential to maintain good control of diabetes.
Type 1 diabetes research takes a step forward
The Fabulinus study represents a significant step forward in type 1 diabetes research. The Florence Meyer, thanks to his commitment, is at the forefront of this important scientific challenge. The results obtained so far are very promising and hold out hope for the development of new, more effective and personalised therapies that improve patients’ quality of life and help them to live a healthier and more independent life.
Sources and images